Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 2:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 73 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vagina Atrophy Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Estrogen and the Urogenital Microbiome in GSM

NCT03336437
View directory record Official record
Conditions
Menopause
Interventions
Estradiol vaginal ring, Placebo vaginal ring
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
40 Years to 89 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women

NCT01400776
View directory record Official record
Conditions
Postmenopausal Vulvovaginal Atrophy
Interventions
WC3011 Estradiol Vaginal Cream, Vehicle
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
35 Years and older · Female only
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
70
States / cities
Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated May 8, 2022 · Synced Sep 12, 2026, 2:07 AM EDT
Terminated Phase 2 Interventional Results available

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

NCT04493333
View directory record Official record
Conditions
Vaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors
Interventions
Vaginal Dehydroepiandrosterone, Vaginal Polycarbophil Moisturizer
Drug · Combination Product
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Investigation of Microbiomes of Postmenopausal Women Looking for Outcomes and Response to Estrogen Therapy

NCT03996603
View directory record Official record
Conditions
Female Urogenital Diseases, Vaginal Atrophy, Postmenopausal Atrophic Vaginitis, Genitourinary Disease, Postmenopausal Symptoms
Interventions
Conjugated Estrogens Cream
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 6, 2024 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

DHEA Against Vaginal Atrophy - Safety Study of 12 Months

NCT01256671
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
31
States / cities
Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects

NCT02747641
View directory record Official record
Conditions
Atrophy, Vaginal Atrophy, Genital Diseases, Female
Interventions
Pixel CO2 Laser System
Procedure
Lead sponsor
Alma Lasers Inc.
Industry
Eligibility
35 Years to 70 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2017 · Synced Sep 12, 2026, 2:07 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Vaginal Creams to Reduce Vaginal Erosion in Pessary Users

NCT02316249
View directory record Official record
Conditions
Atrophy of Vagina, Vaginal Ulceration, Vaginitis
Interventions
Estradiol, placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Sep 12, 2026, 2:07 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Fractional CO2 Laser Therapy Versus 4% Topical Lidocaine Gel for Dyspareunia in Breast Cancer Survivors

NCT03257670
View directory record Official record
Conditions
Dyspareunia
Interventions
4% Topical Lidocaine Gel, CO2RE fractional laser therapy
Drug · Device
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 12, 2026, 2:07 AM EDT
Suspended Phase 1Phase 2 Interventional

Vaginal Testosterone Cream For Atrophic Vaginitis in Women Taking Aromatase Inhibitors for Breast Cancer.

NCT01122342
View directory record Official record
Conditions
Vaginitis, Dyspareunia, Breast Neoplasms
Interventions
Testosterone propionate
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Pawtucket, Rhode Island • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 12, 2010 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Phase 1 Interventional

Study Comparing Premarin® Vaginal Cream Versus Premarin® Oral Tablets in Atrophic Vaginitis

NCT00167921
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Premarin® Vaginal Cream, Premarin® oral tablets
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
45 Years to 80 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
2
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2007 · Synced Sep 12, 2026, 2:07 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

A Prospective Trial to Assess Breast Cancer Survivors and Vaginal Atrophy Treatment Outcomes

NCT03547089
View directory record Official record
Conditions
Vaginal Atrophy, Genitourinary System; Disorder, Female, Vaginal Abnormality, Sexual Dysfunction, Sexual Problem
Interventions
Viveve®
Device
Lead sponsor
W. Grant Stevens, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Marina del Rey, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Phase 3 Interventional

Vagifem Low Dose for Postmenopausal Atrophic Vaginitis Symptoms

NCT00108849
View directory record Official record
Conditions
Menopause, Postmenopausal Vaginal Atrophy
Interventions
estradiol, 10 mcg
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
45 Years and older · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
51
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Phase 3 Interventional

A Clinical Trial to Evaluate the Safety and Efficacy of Enjuvia 0.3 mg for the Treatment of Vulvovaginal Atrophy

NCT00196378
View directory record Official record
Conditions
Menopause
Interventions
Synthetic Conjugated estrogens, B, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Carmichael, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2013 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Evaluation of Fractional Bi-Polar Radio-Frequency for Symptoms of Vulvovaginal Atrophy

NCT05398172
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
MorpheusV Applicator
Device
Lead sponsor
InMode MD Ltd.
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Newport Beach, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Phase 2 Interventional Results available

TXV13-01 Estradiol Vaginal Softgel Capsules in Treating Postmenopausal Women With Symptoms of Vulvar and Vaginal Atrophy

NCT02449902
View directory record Official record
Conditions
Menopause, Vulvovaginal Atrophy, Painful Intercourse, Dyspareunia
Interventions
Estradiol, placebo
Drug
Lead sponsor
TherapeuticsMD
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Dec 13, 2015 · Synced Sep 12, 2026, 2:07 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo

NCT04807894
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Vaginal Atrophy, Postmenopausal Disorder
Interventions
Vaginal Cream with Applicator
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
60 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Sep 12, 2026, 2:07 AM EDT
Not yet recruiting Phase 4 Interventional Accepts healthy volunteers

Vaginal Estradiol vs Moisturizer to Improve Postmenopausal Vaginal Aging Symptoms and the Microbiome in Women Living With HIV

NCT07526948
View directory record Official record
Conditions
Menopausal Complaints, Vaginal Atrophy, Genitourinary Symptoms, HIV (Human Immunodeficiency Virus), Menopause Related Conditions, Vaginitis, Perimenopause
Interventions
Vaginal estradiol tablets, Vaginal moisturizer
Drug · Other
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
40 Years to 70 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Not applicable Interventional

Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause

NCT03178825
View directory record Official record
Conditions
Vaginal Atrophy, Sexual Dysfunction, Dyspareunia, Vaginal Dryness, Chronic UTI
Interventions
Hybrid Fractional Laser
Device
Lead sponsor
Sciton
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Los Gatos, California • Pensacola, Florida • New Orleans, Louisiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 12, 2026, 2:07 AM EDT
Recruiting Phase 2 Interventional

Proof of Concept Study of Vaginal AZU-101 in Vulvovaginal Atrophy in Postmenopausal Women

NCT06197568
View directory record Official record
Conditions
Vulvo Vaginal Atrophy (VVA)
Interventions
Lasofoxifene Tartrate
Drug
Lead sponsor
Azure Biotech Inc.
Industry
Eligibility
45 Years to 60 Years · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Phase 3 Interventional Results available

Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy

NCT01358760
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
32
States / cities
Montgomery, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 12, 2026, 2:07 AM EDT
Completed Phase 4 Interventional Results available

Vulvoscopy Changes of the Vulva, Vestibule and Vagina With Daily Ospemifene in Women With Dyspareunia From VVA

NCT02784613
View directory record Official record
Conditions
Vulvovaginal Atrophy, Dyspareunia
Interventions
Ospemifene
Drug
Lead sponsor
Sue Goldstein
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Sep 12, 2026, 2:07 AM EDT
Recruiting Not applicable Interventional

VALOR: Vaginal Atrophy & Long-term Observation of Recovery

NCT05953090
View directory record Official record
Conditions
Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva, Lichen Planus of Vulva, Lichen Simplex of Vulva (Disorder)
Interventions
7-0940
Device
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
14
States / cities
Birmingham, Alabama • Burbank, California • Laguna Hills, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 12, 2026, 2:07 AM EDT
Recruiting Phase 4 Interventional

Postpartum Vaginal Estrogen for Breastfeeding Patients

NCT05457972
View directory record Official record
Conditions
Breastfeeding, Postpartum Sexual Dysfunction, Vaginal Atrophy
Interventions
Estradiol, Vaginal Moisturizer
Drug · Device
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 12, 2026, 2:07 AM EDT